Gene Expression–Based Risk Score for Prognosis in Diffuse Large B-Cell Lymphoma

Devin J, Kassambara A, Bruyer A, Moreaux J, Bret C. Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact. Journal of Clinical Medicine. 2019. Download the PDF

Summary of the Study

Diffuse large B-cell lymphoma (DLBCL) is the most frequent non-Hodgkin lymphoma. This study integrates flow cytometry and gene expression data to improve the phenotypic classification and prognostic assessment of DLBCL.

• Expression of 27 lymphoid markers was assessed in 16 DLBCL-derived cell lines by flow cytometry

• Gene expression levels of four key markers (BCL2, BCL6, CD11c, LAIR1) were used to build a gene-based risk score

• The score:

  • Stratified patients into four prognostic groups
  • Was an independent predictor of overall survival

• Drug response analysis linked BCL6 overexpression to resistance against etoposide

Important

In this study, Alboukadel Kassambara contributed to the data analysis, specifically the gene expression modeling and construction of the prognostic risk score, linking molecular profiles to clinical outcomes in DLBCL.

Citation

Publication: In Journal of Clinical Medicine
Date: July 22, 2019
Type: Journal Article
PDF: Download the PDF

< Back to all abstracts

Scientific Contributions

Note

Here are more scientific abstracts authored or co-authored by Alboukadel Kassambara. These contributions span computational biology, bioinformatics, biostatistics, machine learning, and multi-omics, with a focus on immuno-oncology and translational research.